Currently out of the existing stock ratings of Andrew Peters, 34 are a BUY (87.18%), 5 are a HOLD (12.82%).

Andrew Peters

Work Performance Price Targets & Ratings Chart

Analyst Andrew Peters, carries an average stock price target met ratio of 91.17% that have a potential upside of 32.46% achieved within 539 days. Previously, Andrew Peters worked at DEUTSCHE BANK, UBS.

Andrew Peters’s has documented 91 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ESPR, Esperion Therapeutics at 03-May-2018.

Wall Street Analyst Andrew Peters

Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for IMGN (IMMUNOGEN) at 6/11/2014. The price target of $13 was fulfilled within 1 day with a profit of $0.87 (7.17%) receiving and performance score of 71.72.

Average potential price target upside

of $604.8 (39.54%) on SNSS (SUNESIS PHARMACEUTICALS).
of $39.25 (29.35%) on AMGN (AMGEN).
of $32.26 (25.94%) on ALXN (ALEXION PHARMACEUTICALS).

BMRN Biomarin Pharmaceutical GILD Gilead Sciences HALO Halozyme Therapeutics NBIX Neurocrine Biosciences ACHN Achillion Pharmaceuticals ALXN Alexion Pharmaceuticals ESPR Esperion Therapeutics PRTA Prothena plc EXEL Exelixis AMGN Amgen BIIB Biogen IMGN ImmunoGen SNSS Sunesis Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Eliana Merle (BARCLAYS)